Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Price Monitoring Extension

April 22, 2021
RNS Number : 3466W Renalytix AI PLC 22 April 2021   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders

Second Price Monitoring Extn

April 22, 2021
RNS Number : 3204W Renalytix AI PLC 22 April 2021   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this

Price Monitoring Extension

April 22, 2021
RNS Number : 3183W Renalytix AI PLC 22 April 2021   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders

10-year US Government contract award

April 22, 2021
RNS Number : 2366W Renalytix AI PLC 22 April 2021     Renalytix AI plc   (" RenalytixAI " or the " Company ")     U.S. General Services Administration Grants 10-Year Governmentwide Contract for RenalytixAI KidneyIntelX Testing   KidneyIntelX Testing Services Available to 140 U.S.

Positive clinical outcome data for KidneyIntelX

April 20, 2021
RNS Number : 9600V Renalytix AI PLC 20 April 2021     Renalytix AI plc   (" RenalytixAI " or the " Company ")     KidneyIntelX Demonstrates Performance and Informs Treatment Decisions in Multinational CANagliflozin CardioVAScular Assessment Study (CANVAS)   Data from 1,325 CANVAS Participants with

Director/PDMR Shareholding

April 19, 2021
RNS Number : 8100V Renalytix AI PLC 19 April 2021     Renalytix AI plc   Director/PDMR Shareholding   New York , 19 April 2021 - Renalytix AI plc   (LSE : RENX) (NASDAQ: RNLX) ("RenalytixAI" or the "Company"), an artificial intelligence -enabled in vitro   diagnostics company, focused on optimizing

Exclusive option agreement

April 14, 2021
RNS Number : 3696V Renalytix AI PLC 14 April 2021       Renalytix AI plc   (" RenalytixAI " or the " Company ")     RenalytixAI and Joslin Diabetes Center Build on Proprietary Kidney Biomarker Portfolio for KidneyIntelX Platform   Agreement provides RenalytixAI with exclusive option to access

Clinical Utility Study

April 8, 2021
RNS Number : 7571U Renalytix AI PLC 08 April 2021       Renalytix AI plc   (" RenalytixAI " or the " Company ")     Clinical Utility Study Demonstrates Primary Care Physicians Highly Likely to Order KidneyIntelX to Inform Care Decisions   Value of KidneyIntelX Testing Demonstrated by Data from 401

Clinical findings published in Diabetologia

April 6, 2021
RNS Number : 4091U Renalytix AI PLC 06 April 2021       Renalytix AI plc   (" RenalytixAI " or the " Company ")     Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure  

Update on Finalization of MCIT Rule

March 15, 2021
RNS Number : 1874S Renalytix AI PLC 15 March 2021   Renalytix AI plc (" RenalytixAI " or the " Company ")   Update on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics   NEW YORK , March 15, 2021 - Renalytix AI plc   (LSE : RENX) (NASDAQ:
Displaying 81 - 90 of 205